The U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.

CDSCO reported top brands of paracetamol, pantoprazole, amoxicillin and other amongst failed samples reported by CDSCO. These samples are reported to be not of standard quality. Total 59 different brands from well known pharmaceutical industries failed to compile with standard quality.

Top brands like Clavam 625, Mexclav 625, Shelcal, Pan D failed various assays and quality tests, which were collected and tested by different Drugs Testing Laboratories.

Torrent Pharma, the flagship Company of Torrent Group is one of the leading pharma companies of the Country. The Company was a pioneer in initiating the concept of niche marketing in India and today is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.